NCT02160223View on ClinicalTrials.gov

Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea

PHASE4CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

Sugammadex

Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery

DRUG

Neostigmine

Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery

Trial Locations (1)

Unknown

Diskapi Yildirim Beyazit Teaching and Research Hospital, Ankara

All Listed Sponsors
lead

Diskapi Teaching and Research Hospital

OTHER

NCT02160223 - Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter